FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 67 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q4 2018. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $5,022,000,000 | +49553.9% | 2,110,071 | -21.8% | 0.56% | -44.3% |
| Q1 2019 | $10,114,000 | -30.4% | 2,697,133 | -33.4% | 1.00% | -45.5% |
| Q4 2018 | $14,531,000 | -37.1% | 4,047,561 | +0.4% | 1.84% | -49.0% |
| Q3 2018 | $23,094,000 | -3.6% | 4,030,268 | -15.7% | 3.60% | +8.4% |
| Q2 2018 | $23,956,000 | -99.9% | 4,781,708 | 0.0% | 3.32% | -8.9% |
| Q1 2018 | $24,530,000,000 | +85257.4% | 4,781,708 | 0.0% | 3.64% | -25.7% |
| Q4 2017 | $28,738,000 | +8.3% | 4,781,708 | 0.0% | 4.90% | -5.0% |
| Q3 2017 | $26,538,000 | +19.6% | 4,781,708 | 0.0% | 5.16% | +29.9% |
| Q2 2017 | $22,187,000 | +21.7% | 4,781,708 | +29.9% | 3.98% | +9.8% |
| Q1 2017 | $18,224,000 | -45.3% | 3,681,708 | +22.7% | 3.62% | -47.1% |
| Q4 2016 | $33,300,000 | +29.8% | 3,000,000 | +8.3% | 6.84% | +4.6% |
| Q3 2016 | $25,645,000 | +1369.6% | 2,769,425 | +908.0% | 6.54% | +1208.2% |
| Q2 2016 | $1,745,000 | – | 274,756 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 4,781,708 | $28,738,000 | 4.90% |
| DSC Advisors, L.P. | 1,187,604 | $7,138,000 | 4.14% |
| Opaleye Management Inc. | 960,000 | $5,769,000 | 1.85% |
| DAFNA Capital Management LLC | 352,741 | $2,120,000 | 1.14% |
| Vivo Capital, LLC | 855,000 | $5,139,000 | 1.10% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 382,838 | $2,301,000 | 0.81% |
| SENZAR ASSET MANAGEMENT, LLC | 377,397 | $2,268,000 | 0.58% |
| Sio Capital Management, LLC | 131,200 | $789,000 | 0.44% |
| Perceptive Advisors | 1,117,324 | $6,715,000 | 0.22% |
| Tekla Capital Management LLC | 930,398 | $5,592,000 | 0.22% |